There are 412 resources available
Invited Discussant LBA57, 1264MO, LBA58 and LBA59
Presenter: Edward Garon
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
Invited Discussant LBA61, 1292MO, LBA62 and 1293MO
Presenter: Matthias Guckenberger
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
IO after or with chemoradiotherapy? For how long?
Presenter: Johan Vansteenkiste
Session: Managing stage III NSCLC in the era of IO
Resources:
Slides
Webcast
Introduction and definition of oligometastatic disease(s) + Case presentation
Presenter: Anne-Marie Dingemans
Session: Management of oligometastatic disease in NSCLC
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Sanjay Popat
Session: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge
Resources:
Webcast
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
1354P - Beyond the common mutation: Examining chemotherapy success in uncommon EGFR mutations
Presenter: Chien-Chung Lin
Session: Poster session 19
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1414P - Impact of co-mutations on the prognosis of targeted therapy in EGFR-mutant advanced NSCLC: A result of real-world study
Presenter: Sisi Pan
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20